Thomas Vollmers

Commercial Leader, Precision Medicine and Companion Diagnostics

Miami-Fort Lauderdale Area

About

Thomas Vollmers is a seasoned Sales and Marketing Executive in the Pharmaceutical and Biotechnology Industry, specializing in Precision Medicine and Companion Diagnostics (CDx). With a proven track record in US and Global CDx Commercialization across therapeutic areas such as HIV, oncology, and allergic disease, Thomas has successfully launched numerous therapeutic and diagnostic products. A dedicated professional, Thomas excels at forging strategic, long-term partnerships with stakeholders in the Therapeutic and CDx ecosystem. His deep understanding of diagnostic platforms, technologies, and trends, combined with his ability to collaborate with diagnostic manufacturers, reference labs, lab networks, and key opinion leaders (KOLs), positions him as an asset in driving the growth and success of healthcare companies. Thomas' distinguished career includes pivotal roles at renowned companies like The Upjohn Company, GlaxoSmithKline, ViiV Healthcare, Pfizer, and Merck. In these roles, he has played a crucial part in the development, implementation, and management of commercial strategies that foster growth and innovation in the therapeutic and companion diagnostics sectors. Core competencies include: • Sales & Marketing • Commercial Strategy • Product Launches • Diagnostic Regulations • KOL Development • Training • Team Leadership • Business Development • Partnership Management • Technology Assessment • Financial Analysis • Market Research • Oncology, Immunology, HIV/AIDS

Experience

  • Head - Strategic Partnerships and Commercial Strategy at AllerGenis
    Aug 2017 - Present · 9 yrs

    Established in 2017 and located in Hatfield, PA, AllerGenis develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess and monitor patients with food allergies. AllerGenis is creating the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights leading to improved patient outcomes.

  • Founding Partner at Lloyd | Garner & Associates
    May 2016 - Present · 10 yrs 3 mos

  • Global Capability Director, Oncology Diagnostics at AstraZeneca
    Apr 2015 - Apr 2016 · 1 yr 1 mo

  • Director, Global Commercial Diagnostics - Immunotherapeutics at GlaxoSmithKline
    Sep 2013 - Oct 2014 · 1 yr 2 mos

  • ViiV Healthcare (Raleigh-Durham, North Carolina Area)
    • Senior Director, Companion Diagnostics
      Nov 2010 - Sep 2013 · 2 yrs 11 mos

    • Senior Product Director, Selzentry
      Nov 2009 - Oct 2010 · 1 yr